PATENT CLAIM ANALYSIS

Application Number: 16269213
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "660000"]

Abstract:
A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).

Claim (Index 16):
A method of administering tramadol for treating acute pain in a human patient(s) via an intravenous dosing regimen, comprising\n intravenously administering a first dose of tramadol to a human patient(s) experiencing acute pain in an amount of about 60 mg; and thereafter intravenously administering additional doses of tramadol to the human patient(s) in an amount of about 60 mg tramadol at dosage intervals of about 6 hours, except that a second dose is intravenously administered as a loading dose at a shortened interval as compared to the dosage interval of about 6 hours, such that a total of 5 doses of 60 mg tramadol are intravenously administered on the first day of treatment and the intravenous tramadol is administered on subsequent days of treatment on a basis of a total of 4 doses of 60 mg tramadol per day until the intravenous tramadol administration is terminated, and wherein the tramadol is tramadol base or a pharmaceutically acceptable salt of tramadol, such that the intravenous dosing regimen provides a steady-state Cmax of tramadol which is similar to the steady-state Cmax of 100 mg tramadol HCl given every 6 hours, and administering another analgesic before, concurrently with, or after administration of the tramadol, thereby treating the acute pain in the subject.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 99.0
- Lexical Diversity: 2.34831
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16223522', '16223556', '15622910', '15612665', '15163111']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8654343024277962
- 35 USC 102 Novelty (BERT): 0.7350819918452195
- Combined Prediction Score: 0.8523990713695386
- Mean Citation Score: 823.0225620000001
- Max Citation Score: 831.9936
- Similarity Product: 801.1570223258972

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test